Penultimate draft --please cite the published paper: Wendler D, Rid A: Genetic Research on Biospecimen Poses Minimal Risk. Trends in Genetics 2015; (1):11-- 15 5 A second source of risk to donors comes from incidental research findings. These risks are becoming increasingly likely with expanded use of whole-exome and whole-genome sequencing [13] . For example, research on genetic risk factors for cardiac disease might also identify variants correlated with increased risk for breast cancer. Although incidental findings are disclosed only when the potential benefits are thought to justify the risks, disclosure can cause stress, anxiety, or negative effects on donors' self-image [14] . Donors may also undergo risky procedures (e.g. mastectomy) based on incidental findings. The fact that some risks to donors remain, even when standard protections have been implemented, raises the question of whether these risks are minimal or greater than minimal [Box 1].
Genetic Research: Minimal Risk on the 'Risks of daily life' Standard
There is widespread agreement that it is ethically acceptable to expose research participants to some risks in order to collect data to benefit future patients, provided the risks are sufficiently low [15] . Yet, it can be difficult to determine when individual risks are acceptably low: Is an estimated risk to donors of approximately 1 in 10,000 of being denied long-term care insurance acceptable? Or should it trigger additional requirements and limitations, even though they increase the costs of research and may limit what studies can be conducted?
To date, there have been no systematic analyses of the risks of genetic research on biospecimens. As a result, review committees and other stakeholders rely largely on their own intuitions. Unfortunately, intuitive risk judgments are subject to well-documented cognitive biases [16] . For example, we tend to judge unfamiliar activities as posing greater risks than familiar ones. This bias is particularly problematic in the context of research which often involves novel interventions and methods. In addition, intuitive judgments about which research
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To avoid the problems engendered by relying on intuition alone, some regulations direct review committees to evaluate research by comparing its risks to the risks of other specified activities. The most common approach, included in US regulations [17, 18] , defines research risks as minimal when they do not exceed the risks ordinarily encountered in daily life or during routine examinations [19] . Daily life poses a relatively high likelihood of minor harms (e.g.
scrapes and bruises) and a very low -but not zero -likelihood of serious harm. For example, playing soccer poses approximately a 1 in 10,000 chance of complete ligament tear, while the average car ride poses at least a 1 in 1,000,000 chance of death [20] . Under the risks of daily life standard, whether genetic research on biospecimens qualifies as minimal risk or greater than minimal risk depends on whether the risks exceed these and other risks in daily life.
A literature search identified no reported cases in which donors experienced significant harm as a result of their samples being used for genetic research. We did find reported cases of genetic discrimination in the US [see: http://assets.opencrs.com/rpts/RL33903_20070307.pdf].
However, these cases predate the adoption of GINA and did not involve research.
The extent to which an absence of reports of serious harm suggests that no serious harms have occurred depends on the circumstances. Consider first a case in which investigators give an experimental drug to a few research participants and have limited contact with them afterwards.
In this case, an absence of reports of harm provides very weak evidence that no harms have occurred. Contrast this with a case in which investigators give a drug that poses a risk of painful peripheral neuropathy to thousands of research subjects, and have contact with them for years.
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The absence of reports of serious harms from genetic research on biospecimens seems more 
The 'Routine Examinations' Standard
Many activities in daily life pose risks that would be excessive in the research setting (e.g. mountain climbing, riding a motorcycle). With this in mind, some commentators propose to limit the 'risks of daily life' standard to the risks posed by routine examinations for healthy individuals [21] . Because the risks of routine examinations for healthy individuals tend to be very low, these commentators argue that this comparison offers a way to evaluate whether the risks of genetic research are acceptably low.
Many healthy adults undergo genetic testing [22] , including testing for risks of various diseases (e.g. colon cancer, breast cancer) [23] . Some of this testing, in particular some direct-toconsumer genetic testing, poses inappropriate risks due to inaccurate results and lack of followup. The fact that the risks of genetic testing in the clinical setting are considered acceptable for children is especially important. It is widely agreed that children deserve greater protection in research than adults [26] . Hence, if a given level of risk is appropriate for evaluating the acceptability of the risks of research with children, it should be appropriate for evaluating the acceptability of the risks of research with adults. This suggests that we can evaluate whether the Genetic samples and results are available to many more individuals in clinical practice than in research, and they tend to be stored together with the patient's personal information.
Next, a significantly greater number of genes typically are assessed in research than in clinical practice, especially in studies involving whole-exome and whole-genome testing.
Research is therefore likely to pose greater risks with respect to discovering and disclosing potentially significant findings. However, it is important to recognize that these findings are disclosed only when the potential benefits to donors are thought to justify the risks [27] . This suggests that the increased risks of disclosure of incidental findings in research typically are offset by increased potential benefits for donors. In addition, as whole-exome and whole-genome testing become more reliable and less expensive, they likely will be incorporated into the clinical setting [28, 29] . For example, some commentators predict that, in the near future, whole-genome sequencing may be included in newborn screening programs [30, 31] .
These considerations suggest that genetic research on biospecimens overall poses similar risks to genetic testing in clinical practice. It follows that the risks of genetic research on
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It follows that most genetic research on biospecimens poses minimal risk. This conclusion suggests that IRBs and other stakeholders should begin with the assumption that genetic research which includes standard protections for donor confidentiality poses minimal risk. IRBs should then consider whether there are any factors present in individual cases that might increase the risks to donors and possibly make the research more than minimal risk.
Exceptions
Population-level risk determinations always admit of exceptions. The claim that a single blood draw is minimal risk does not preclude the possibility that it poses higher risks to some individuals (e.g. those with serious bleeding disorders). Similarly, investigators and IRBs should be aware that, even with standard safeguards in place, some genetic research on biospecimens may pose greater than minimal risk.
In general, the possibility that the risks of genetic research may be greater than minimal arises when the chances of inappropriate disclosure are above average and disclosure could lead to more serious harm for donors. When might these conditions arise [Box 2]? The likelihood of harm may increase when one or more of the standard confidentiality protections cannot be implemented. For example, risks would increase if investigators are not able to limit access to the computer which contains the code to donors' identities. The chances of harm may also increase when these measures are not sufficient to protect donor confidentiality. This might be the case in research on diseases that affect a very small number of individuals.
Penultimate
Possible harms may be more significant for donors who are particularly vulnerable. One example might be research on genes associated with sensitive conditions (e.g. schizophrenia, drug abuse), where testing results could lead to significant harm if obtained by the wrong parties.
The likelihood and magnitude of harm may also increase in certain social and legal contexts (e.g.
societies with high stigma against psychiatric conditions). When one or more of these factors is present, investigators and IRBs should consider incorporating additional protections and limitations (e.g. further data protection measures, restrictions on sample sharing, removal of personal identifiers).
Concluding remarks
Genetic research on human biospecimens has significant scientific potential. At the same time, it is important to ensure that the donors of biospecimens are appropriately protected. Determining whether and when additional protections and limitations are needed to achieve this goal is made difficult by continuing debate over whether this research poses minimal risk or greater than minimal risk. The present analysis reveals that, with appropriate safeguards in place, most genetic research on human biospecimens poses minimal risk to donors. This conclusion suggests that existing protections should be sufficient and that only in exceptional cases should review committees consider mandating additional protections and limitations.
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1. The present analysis argues that the absence of reports of significant harm experienced by sample donors suggests that genetic research on biospecimens poses minimal risk to donors.
Future research might evaluate this conclusion by following a cohort of donors over time and systematically collecting data on any harms they experience. This research also would be valuable for identifying any additional circumstances under which genetic research on biospecimens might pose greater than minimal risk.
2. The present analysis focuses on risks to individual donors. Some genetic research on biospecimens also poses risks to the groups to which donors belong. Because risks to groups tend to be context dependent, IRBs typically should review them on a case-by-case basis, using a process that includes input from members of the groups in question [35] . 
